Compare IPSC & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | INFU |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 277.6M |
| IPO Year | 2021 | 2005 |
| Metric | IPSC | INFU |
|---|---|---|
| Price | $1.72 | $15.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.75 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 1.0M | 134.0K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.30 | ★ 181.82 |
| EPS | N/A | ★ 0.35 |
| Revenue | $109,164,000.00 | ★ $143,436,000.00 |
| Revenue This Year | N/A | $1.42 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ N/A | $43.49 |
| Revenue Growth | ★ 1556.76 | 6.36 |
| 52 Week Low | $0.44 | $7.29 |
| 52 Week High | $2.97 | $15.33 |
| Indicator | IPSC | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 64.30 |
| Support Level | $1.29 | $11.97 |
| Resistance Level | $1.75 | N/A |
| Average True Range (ATR) | 0.16 | 0.72 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 60.38 | 87.72 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.